EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Physiologically‐Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges

James W T Yates iD, Michael Zientek, Kunal S Taskar iD, Wen Lin, Tycho Heimbach iD, Stefan Willmann iD, Jessica Rehmel iD, Neil Parrott iD, Michael Hanley, Justine Badee, Yuan Chen iD, Susan Cole und 15 weitere

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70141 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von James W T Yates und 26 weiteren Autor:innen. Beteiligte Einrichtung: DMPK, Preclinical Sciences, GSK, Stevenage, UK. Hauptthemen laut MEDLINE: Models, Biological, Drug Development, Pharmacokinetics. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric extrapolation strategies issued by health authorities have streamlined pediatric drug development and reduced the unnecessary burden of conducting pediatric clinical studies. In line with these strategies, physiologically based pharmacokinetic (PBPK) models have been utilized extensively for initial dosing regimen and sampling timepoint selection for pediatric studies, as well as dose validation throughout pediatric drug development. Here, the status and challenges of PBPK modeling in pediatric drug development have been summarized by the IQ Pediatric PBPK Working Group. Our work reviews current practices for pediatric PBPK modeling across various therapeutic areas. To enable best practice, we propose an optimized workflow for pediatric PBPK modeling recommendations. Two selected key pediatric PBPK case examples are also described, where modeling impacted the drug label extension to pediatric patients. Moreover, we analyze the current gaps and challenges in our understanding of drug absorption, distribution, metabolism, and elimination in pediatric PBPK model development. Since neonates are the least studied and the most medically fragile, the depth of our understanding of their rapidly evolving physiological processes is limited and so there exist significant modeling gaps which we summarize here. Finally, we provide recommendations, including building a public data repository, leveraging real‐world data, and implementing microdose studies for addressing pediatric PBPK modeling challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalDrug DevelopmentPharmacokineticsHumansChildPediatricsInfant, Newborn

Autor:innen und Institutionen

  • DMPK, Preclinical Sciences, GSK, Stevenage, UK.
  • Takeda Development Center Americas, Cambridge, Massachusetts, USA.
  • Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. FDA, Silver Spring, Maryland, USA.
  • Pharmaceutical Sciences and Clinical Supply, Merck & co., Inc., Rahway, New Jersey, USA.
  • Bayer AG, Research & Development Pharmaceuticals, Pharmacometrics/Modeling & Simulation, Wuppertal, Germany.
  • Global Pharmacokinetics, Pharmacodynamics, and Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: James W T Yates, Kunal S Taskar, Tycho Heimbach, Stefan Willmann, Jessica Rehmel, Neil Parrott, Yuan Chen, Loeckie De Zwart, Sebastian Haertter, Jan Wahlstrom

Zitieren

APA

Yates, J. W. T., Zientek, M., Taskar, K. S., Lin, W., Heimbach, T., Willmann, S., Rehmel, J., Parrott, N., Hanley, M., Badee, J., Chen, Y., Cole, S., De Zwart, L., Haertter, S., Jiang, R., Kotsuma, M., Liang, G., Lin, Y. W., Liu, J., …, & Cheung, S. Y. A. (2026). Physiologically‐Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70141

Vancouver

Yates JWT, Zientek M, Taskar KS, Lin W, Heimbach T, Willmann S, et al. Physiologically‐Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70141

BibTeX
@article{Yates2026,
  author = {Yates, James W T and Zientek, Michael and Taskar, Kunal S and Lin, Wen and Heimbach, Tycho and Willmann, Stefan and Rehmel, Jessica and Parrott, Neil and Hanley, Michael and Badee, Justine and Chen, Yuan and Cole, Susan and De Zwart, Loeckie and Haertter, Sebastian and Jiang, Rongrong and Kotsuma, Masakatsu and Liang, Guiqing and Lin, Yu-Wei and Liu, Jing and Ou, Ying and Rascher, Juliane and Shaik, Naveed A and Wahlstrom, Jan and Wang, Xiaofeng and Xiao, Guangqing and Yee, Ka Lai and Cheung, S Y Amy},
  title = {Physiologically‐Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70141}
}
Kostenlos starten →